Zinc supplementation in type-2 diabetes: a randomized clinical trial and molecular studies of the mechanisms involved

niversity of Chile, Faculty of Medicine0 个研究点目标入组 80 人开始时间: 2016年2月23日最近更新: 2016年10月17日

适应症

试验速览

暂无简介。

•1. Men and women with type-2 diabetes (<10 years since diagnosis)
•2. Thirty to 65 years old
•3. BMI 20-40 kg/m2
•4. Stable body weight (weight variation <5%) for at least 3 months prior to screening
•5. Glycated hemoglobin (HbA1c) <9 % and/or fasting glycemia <180 mg/d

•1. Insulin therapy.
•2. History of ketoacidosis or hyperosmolar hyperglycemic nonketotic syndrome in the previous 6 months.
•3. Estimated glomerular filtration rate <60 mL/min.
•4. Alanine aminotransferase or aspartate aminotransferase >2.5 times the upper normal limit.
•5. Congestive heart failure (grade III-IV according to the New York Heart Association criteria, 1994)
•6. Uncontrolled hypertension
•7. History of stroke, transient ischemic attack or acute myocardial infarction (previous 5 years). Recent surgery or acute infection (previous 3 months)
•8. Major psychiatric disorder affecting compliance
•9.. Use of antipsychotic medications
•10. Systemic use of glucocorticoid steroids within previous 6 weeks
•11. Alcohol intake =2 drinks/day
•12. Cancer diagnosis or treatment in the past 5 years, with the exception of cancers that have been cured, and carry a good prognosis
•13. HIV positivity
•14. Pregnant or lactating women
•15. Having taken vitamins mineral supplements in the previous 3 months

发起方

niversity of Chile, Faculty of Medicine